

Lacking advanced therapy options?

ActiGraft provides clinicians with wound management for patients with limited treatment options due to the complexity of wounds and reimbursement structures associated with different therapies.

Choose ActiGraft for your lost patients today.



Medicare Advantage coverage available via NCD 270.3.



20 weeks of coverage via NCD 270.3 & code G0465.



For patients who have exhausted their allowed CTP applications, ActiGraft provides an option for **continued therapy**.



Patients with exposed bone & tendon are **not excluded** from the NCD coverage.



ActiGraft can be applied on **large** and **irregular** wounds up to 56 cm², offering excellent versatility.



Inclusive treatment solution for culturally and religiously sensitive patients – no bovine, porcine, placental, or any other 3rd party products.

An autologous, point-of-care wound management solution created from a patient's peripheral whole blood. Once applied, ActiGraft serves as a protective covering and may optimize the body's own healing potential.

For full safety information, visit www.legacymedicalconsultants.com/actigraft-safety-info



Eligible for reimbursement with Medicare and Medicare Advantage Plans.

ActiGraft is described by the National Coverage Determination (NCD 270.3) as a blood-derived product for non-healing wounds and is eligible for reimbursement nationally from Medicare and Medicare Advantage with HCPCS G0465.

HCPCS Code	HCPCS Description	Status Indicator	APC	Medicare National Average Payment Rate
G0465	Autologous platelet rich plasma (PRP) or other bloodderived product for diabetic chronic wounds/ulcers, using an FDA-cleared device for this indication, (Includes as applicable administration, dressings, phlebotomy, centrifugation or mixing, and all other preparatory procedures, per treatment)	T	5054	PHYSICIAN \$83.84 FACILITY \$2,107.97 NON-FACILITY \$1,064.49

CMS will cover autologous PRP for the treatment of chronic non-healing diabetic wounds for a duration of 20 weeks, when prepared by devices whose Food and Drug Administration (FDA)-cleared indications include the management of exuding cutaneous wounds, such as diabetic ulcers. Coverage and reimbursement depend on individual payer policies, medical necessity, and clinical documentation.

ActiGraft Intended Use

The ActiGraft is intended to be used at point-of-care for the safe and rapid preparation of Whole Blood Clot (WBC) from a small sample of a patient's own peripheral blood. Under the supervision of a healthcare professional, the WBC produced by the ActiGraft is topically applied for the management of exuding cutaneous wounds, such as leg ulcers, pressure ulcers, diabetic ulcers, and mechanically or surgically-debrided wounds.



Healing is in Our Blood

Order and Customer Support



Phone: (817) 961-1288

Fax: (866) 300-0431

www.legacymedicalconsultants.com

customerservice@legacymedicalconsultants.com

ActiGraft Reimbursement Coverage Support

Program Support:

(919) 589-3965

adiorio@prodatamgmt.com

Choose with Confidence